Clinical Trial Update: Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating durvalumab with grid therapy for non-small cell lung cancer progressing during or after the PACIFIC regimen; the study is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 1 | Status: TERMINATED